Table 4.
Odds ratios (95% confidence intervals) of having tumor characteristics with worse prognosis (relative to better prognosis or no cancer) and for of having tumor characteristics with better prognosis (relative to worse prognosis or no cancer) for digital vs. film mammography, Breast Cancer Surveillance Consortium 2003–2011
| Cancer Characteristic | Screen-detected Cancers | Interval Cancers | ||
|---|---|---|---|---|
| Unadjusted OR (95% CI) | Adjusted OR* (95% CI) | Unadjusted OR (95% CI) | Adjusted OR* (95% CI) | |
| All | ||||
| Cancer diagnosis | 1.01 (0.94, 1.09) | 1.06 (0.97, 1.16) | 0.94 (0.81, 1.08) | 0.93 (0.78, 1.10) |
| Unfavorable prognosis: | ||||
| Invasive cancer | 0.92 (0.85, 0.90) | 0.98 (0.89, 1.07) | 0.91 (0.79, 1.04) | 0.90 (0.77, 1.06) |
| For invasive cancers: | ||||
| AJCC Stage IIB or later | 0.85 (0.70, 1.02) | 1.02 (0.85, 1.23) | 0.82 (0.68, 1.01) | 0.69 (0.52, 0.93) |
| Regional or distant SEER summary stage*** | 0.84 (0.74, 0.95) | 1.07 (0.93, 1.24) | 0.80 (0.68, 0.94) | 0.78 (0.64, 0.95) |
| Tumor size >20 mm | 0.87 (0.76, 1.00) | 0.96 (0.81, 1.14) | 0.94 (0.78, 1.13) | 0.83 (0.66, 1.04) |
| Positive nodal status | 0.84 (0.75, 0.95) | 1.07 (0.93, 1.24) | 0.81 (0.69, 0.95) | 0.78 (0.64, 0.95) |
| Grade III | 0.82 (0.73, 0.92) | 0.99 (0.85, 1.15) | 0.89 (0.72, 1.09) | 0.84 (0.67, 1.06) |
| Estrogen receptor negative | 0.86 (0.73, 1.00) | 0.96 (0.78, 1.18) | 0.81 (0.64, 1.03) | 0.71 (0.56, 0.91) |
| Favorable prognosis: | ||||
| DCIS | 1.31 (1.17, 1.46) | 1.30 (1.15, 1.48) | 1.19 (0.88, 1.60) | 1.19 (0.71, 1.98)** |
| For invasive cancers: | ||||
| AJCC Stage IIA or earlier | 0.97 (0.88, 1.06) | 0.99 (0.90, 1.09) | 0.99 (0.86, 1.15) | 1.03 (0.85, 1.24) |
| Local SEER summary stage*** | 0.96 (0.88, 1.04) | 0.95 (0.87, 1.05) | 1.01 (0.86, 1.18) | 0.99 (0.80, 1.24) |
| Tumor size <=20 mm | 0.95 (0.86, 1.05) | 1.00 (0.90, 1.11) | 0.93 (0.79, 1.09) | 0.97 (0.80, 1.19) |
| Negative nodal status | 0.95 (0.88, 1.03) | 0.96 (0.87, 1.05) | 0.99 (0.84, 1.16) | 0.97 (0.78, 1.21) |
| Grade I or II | 1.00 (0.91, 1.09) | 1.01 (0.90, 1.12) | 1.00 (0.84, 1.19) | 1.01 (0.83, 1.24) |
| Estrogen receptor positive | 1.00 (0.91, 1.10) | 0.97 (0.88, 1.07) | 1.04 (0.90, 1.21) | 0.98 (0.81, 1.18) |
*
Odds ratios are adjusted for current hormone therapy use, age, race/ethnicity, screening interval, exam year, and BCSC registry. Bolded ORs indicate those that are significant.
**
Models adjusting for screening interval or race did not converge.
***
The SEER summary stages are local, regional, and distant